Business
Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced the pricing of a private placement with gross proceeds of up to USD 400 million priced at the market under Nasdaq rules. The financing was led by existing investor BVF Partners L.P. and included participation from Aberdeen Investments, Avidity Partners, Coastlands Capital, EcoR1 Capital, Janus Henderson Investors, OrbiMe
About this update from Immunic, Inc.
[{"type":"text","content":"– Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds –","length":104,"tagName":"p","attribs":{}},{"type":"text","content":"– Expected to Fund Completion of Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis, Initiation of Phase 3 Trial in Primary Progressive Multiple Sclerosis, and Transition into a Commercial Organization –","length":206,"tagName":"p","attribs":{}},{"type":"text","content":"– Simona Skerjanec, Former SVP, Global Head of Neuroscience and Rare Diseases at Roche, Elevated to Interim Chairperson of the Board of Directors –","length":147,"tagName":"p","attribs":{}},{"type":"text","content":"– Thor Nagel, Principal at BVF Partners L.P., Joins Board of Directors –","length":72,"tagName":"p","attribs":{}},{"type":"text","content":"– Simona Skerjanec and Dr. Daniel Vitt to Lead Search for CEO with Commercial Background –","length":90,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, Feb. 13, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced the pricing of a private placement with gross proceeds of up to USD 400 million priced at the market under Nasdaq rules. The financing was led by existing investor BVF Partners L.P. and included participation from Aberdeen Investments, Avidity Partners, Coastlands Capital, EcoR1 Capital, Janus Henderson Investors, OrbiMed, RA Capital Management, TCGX, Trails Edge Capital Partners, Vivo Capital, Woodline Partners LP, and other institutional investors.","length":687,"tagName":"p"},{"type":"image","alt":"Immunic, Inc. Logo (PRNewsfoto/Immunic, Inc.)","displaySize":"","headline":null,"caption":"Immunic, Inc. Logo (PRNewsfoto/Immunic, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":116,"url":"https://media.zenfs.com/en/prnewswire.com/662f0f4e6e30b02c00067661328d85b5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7xB1WBN9E4Qdngr88LdRsQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIwNDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/662f0f4e6e30b02c00067661328d85b5","width":400,"height":116}},"href":"https://mma.prnewswire.com/media/871073/Immunic_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content"...